Buy & Sell Medtronic PLC (MDT) – Medtronic PLC Price Today
Aura AI Summary
Key Stats
- $97.77BMarket Cap
- HealthSector
- -24.51%3M Drawdown
- $117.46BEnterprise Value
- 3.73%Dividend Yield
- 68 daysTypical Hold Time
Medtronic PLC (MDT) is currently valued at a market capitalization of $97.77B, with an enterprise value of $117.46B. Over the past 52 weeks, Medtronic PLC has traded between a low of $76.15 and a high of $105.35, highlighting its annual price range. Over the past three months, Medtronic PLC has recorded a drawdown of -24.51%, reflecting recent price volatility. Medtronic PLC offers a dividend yield of 3.73%, with the most recent dividend of $0.71 paid on 27 Mar 26. On average, investors hold Medtronic PLC for approximately 68 days, indicating typical investor behavior on the platform.
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Most Recent News
BTS Group to present Q1 2026 interim report on May 21 with live Q&A session
BTS Group AB, a global consultancy specializing in strategy execution and people development, will present its Q1 2026 interim report on May 21 at 08:00 am CEST. The presentation, led by CEO Jessica Skon and moderated by analyst Johan Sundén, will be...
Chinese crude oil imports drop 20% in April, easing pressure on global oil prices.
China's crude oil imports fell 20% month-over-month in April to 8.2 million barrels per day, the lowest in two years and nearly 30% below pre-war levels. This significant drop, equivalent to Japan's total daily oil consumption, may help ease the upwa...
Anaveon presents positive ANV600 cancer drug data at ASCO 2026, seeks partners for oncology assets.
Anaveon announced positive Phase 1 clinical data for its cancer drug ANV600, showing safety and early tumor shrinkage benefits, at the ASCO 2026 meeting. ANV600 targets PD-1 to boost immune response against tumors, including in resistant cases, and i...
